18 32

Cited 0 times in

Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea

Authors
 Seung Hoon Beom  ;  Jisu Oh  ;  Tae-Yong Kim  ;  Kyung-Hun Lee  ;  Yaewon Yang  ;  Koung Jin Suh  ;  Hyeong-Gon Moon  ;  Sae-Won Han  ;  Do-Youn Oh  ;  Wonshik Han  ;  Tae-You Kim  ;  Dong-Young Noh  ;  Seock-Ah Im 
Citation
 CANCER RESEARCH AND TREATMENT, Vol.49(2) : 454-463, 2017-04 
Journal Title
 CANCER RESEARCH AND TREATMENT 
ISSN
 1598-2998 
Issue Date
2017-04
MeSH
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents / administration & dosage ; Antineoplastic Agents / adverse effects ; Antineoplastic Agents / therapeutic use* ; Aromatase Inhibitors / administration & dosage ; Aromatase Inhibitors / adverse effects ; Aromatase Inhibitors / therapeutic use* ; Biomarkers, Tumor ; Breast Neoplasms / drug therapy* ; Breast Neoplasms / metabolism* ; Breast Neoplasms / mortality ; Breast Neoplasms / pathology ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Letrozole ; Middle Aged ; Neoplasm Metastasis ; Nitriles / administration & dosage ; Nitriles / adverse effects ; Nitriles / therapeutic use* ; Postmenopause* ; Receptor, ErbB-2 / metabolism ; Receptors, Estrogen / metabolism* ; Receptors, Progesterone / metabolism* ; Republic of Korea ; Survival Analysis ; Treatment Outcome ; Triazoles / administration & dosage ; Triazoles / adverse effects ; Triazoles / therapeutic use*
Keywords
First-line treatment ; Hormone receptor-positive ; Korea ; Letrozole ; Metastatic breast cancer
Abstract
Purpose: Letrozole showed efficacy and generally favorable toxicities, along with the convenience of oral administration in postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer (MBC). To the best of our knowledge, there have been no reports of the clinical outcomes in Korean patients, although letrozole is widely used in practice. Therefore, this studywas conducted to affirm the efficacy and toxicities of letrozole in Korean patients. Materials and methods: This study retrospectively analyzed 84 HR-positive MBC patients who had been treated with letrozole from January 2001 to December 2012. Clinicopathological characteristics and treatment history were extracted from medicalrecords. All patients received 2.5 mg letrozole once a day until there were disease progressions or unacceptable toxicity. Progression-free survival (PFS) was the primary endpoint, and secondary endpoints were overall survival (OS), objective response rate (ORR), and toxicity. Results: The median age of the subjects was 59.3 years. Letrozole treatment resulted in a median PFS of 16.8 months (95% confidence interval [CI], 9.8 to 23.8) and a median OS of 56.4 months (95% CI, 38.1 to 74.7). The ORR was 36.9% for the 84 patients with measurable lesions. Multivariate analysis revealed symptomatic visceral disease (hazard ratio, 3.437; 95% CI, 1.576 to 7.495; p=0.002) and a disease-free interval ≤ 2 years (hazard ratio, 2.697; 95% CI, 1.262 to 5.762; p=0.010) were independently associated with shorter PFS. However, sensitivity to adjuvant hormone treatment was not related to PFS. Letrozole was generally well tolerated. Conclusion: Letrozole showed considerable efficacy and tolerability as a first-line treatment in postmenopausal patients with HR-positive MBC.
Files in This Item:
T201706154.pdf Download
DOI
10.4143/crt.2016.259
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Beom, Seung Hoon(범승훈) ORCID logo https://orcid.org/0000-0001-7036-3753
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/178314
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links